INNOVATE (VATE) Q2 2026 earnings summary

Executive summary

• Q2 2026 consolidated revenue rose 74.2% year-over-year to $421.6M, driven by record Infrastructure segment performance, while Life Sciences and Spectrum saw declines.

• Net income attributable to shareholders was $10.4M ($0.71 per diluted share), reversing a prior-year loss of $22M.

• Adjusted EBITDA increased to $46.3M from $15.7M year-over-year, led by Infrastructure and Life Sciences improvements.

• Strategic actions included major refinancing, a pending sale of a controlling interest in Broadcasting to CONX Corp., and ongoing asset disposition processes.

• DBMG delivered record results, MediBeacon expanded commercial momentum, and R2 Technologies showed strong global demand but faced liquidity constraints.

Financial highlights

• Infrastructure revenue increased 77.6% to $414M, with Adjusted EBITDA up to $48.7M from $19.3M year-over-year.

• Life Sciences revenue declined 31.3% to $2.2M, mainly due to lower R2 unit sales; Adjusted EBITDA losses narrowed.

• Spectrum/Broadcasting revenue was $5.4M, with Adjusted EBITDA of $0.4M, impacted by network terminations.

• Cash and equivalents were $87.8M as of June 30, 2026, down from $108.2M at year-end 2025.

• Total principal outstanding indebtedness was $626.4M, up from $617.5M at year-end 2025.

Outlook and guidance

• DBMG expects continued backlog growth and strong revenue visibility into 2027–2028, supported by a robust pipeline and secular demand trends.

• Life Sciences aims to expand commercial placements, reimbursement, and clinical validation for MediBeacon, with pivotal clinical studies for TGFR Sensor targeted in 2027.

• R2 anticipates further global expansion and is seeking additional capital to support scaling and commercial growth.

• Management expects substantial changes to business, cash flow, and financial position due to ongoing asset sales and debt restructuring.

• Substantial doubt exists about the ability to continue as a going concern due to upcoming debt maturities and liquidity risks.